Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Looks to Sell $450M in Common Stock

Premium

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced that it is planning to sell $450 million of its common stock in a public offering.

The company said that it intends to use the proceeds of the offering for general corporate purposes including the continued advancement of its pipeline of RNAi therapeutics, as well as for working capital and general and administrative expenses.

All of the shares in the offering are being sold by Alnylam.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.